Mark Erlander's most recent trade in Cardiff Oncology Inc was a trade of 758,400 Stock Options done . Disclosure was reported to the exchange on March 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 758,400 | 2,925,098 | - | - | Stock Options | |
| Cardiff Oncology Inc | Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 510,000 | 2,170,310 | - | - | Stock Options | |
| Cardiff Oncology Inc | Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 482,064 | 1,664,477 | - | - | Stock Options | |
| Cardiff Oncology Inc | Mark Erlander | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 25 Nov 2022 | 10,000 | 24,481 (0%) | 0% | 1.4 | 14,300 | Common Stock |
| Cardiff Oncology Inc | Mark Erlander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 370,128 | 1,185,400 | - | - | Stock Options | |
| Cardiff Oncology Inc | Mark Erlander | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.34 per share. | 23 Mar 2021 | 965 | 14,481 (0%) | 0% | 10.3 | 9,980 | Common Stock |
| Cardiff Oncology Inc | Mark Erlander | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 260 | 0 | - | - | Restricted Stock Units | |
| Cardiff Oncology Inc | Mark Erlander | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 260 | 13,629 (0%) | 0% | 0 | Common Stock | |
| Cardiff Oncology Inc | Mark Erlander | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2021 | 113 | 13,516 (0%) | 0% | 0 | Common Stock |